The SKCCC at Johns Hopkins
Welcome,         Profile    Billing    Logout  
 56 Trials 
29 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wolff, Antonio C
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
Song, Danny Y
RAVENS, NCT04037358: RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

Active, not recruiting
2
64
US
Radium-223, stereotactic ablative radiotherapy (SABR)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Defense Congressionally Directed Medical Research Program, Bayer
Prostate Cancer
12/26
12/28
Emens, Leisha A
TBCRC 048, NCT03344965: Olaparib in Metastatic Breast Cancer

Active, not recruiting
2
114
US
Olaparib, AZD2281, KU-0059436
Beth Israel Deaconess Medical Center, Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
07/25
12/25
NCT03804944: Converting HR+ Breast Cancer Into an Individualized Vaccine

Recruiting
2
100
US
Focal Radiation therapy, Pembrolizumab (200mg IV for 30 minutes, CDX-301
Weill Medical College of Cornell University, United States Department of Defense, Merck Sharp & Dohme LLC, Celldex Therapeutics
Breast Cancer
12/25
12/27
NCT04875806: A Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors

Terminated
1/2
40
US
NC762
NextCure, Inc.
Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
01/24
01/24
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
Redmond, Kristin
NCT05768919: Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

Recruiting
1/2
30
US
Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
SignPath Pharma, Inc., Avance Clinical Pty Ltd.
Glioblastoma
02/26
05/27
Canon, NCT06463262: Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma

Recruiting
N/A
40
US
ctDNA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Canon Medical Systems, USA
Chordoma of Spine, Chordoma of Skull Base, Chordoma of Sacrum
07/29
07/31
NCT03377517: Radiosurgical Hypophysectomy for Bone Metasteses Pain

Recruiting
N/A
16
US
radiosurgical hypophysectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Accuray Incorporated
Bone Metastases
12/27
12/30
Kleinberg, Lawrence
NCT05768919: Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

Recruiting
1/2
30
US
Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
SignPath Pharma, Inc., Avance Clinical Pty Ltd.
Glioblastoma
02/26
05/27
NCT03961971: Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Active, not recruiting
1
16
US
MBG453, spartalizumab, stereotactic radiosurgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Novartis Pharmaceuticals
Glioblastoma Multiforme
11/22
09/25
CA209-594, NCT02989636: Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma

Active, not recruiting
1
21
US
Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Bristol-Myers Squibb, Chordoma Foundation
Chordoma
04/24
11/26
NCT05083754: Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Recruiting
1
50
US
Retifanlimab, INCMGA00012, Temozolomide, Radiation Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Glioblastoma Multiforme
01/26
01/27
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
NCT03377517: Radiosurgical Hypophysectomy for Bone Metasteses Pain

Recruiting
N/A
16
US
radiosurgical hypophysectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Accuray Incorporated
Bone Metastases
12/27
12/30
Hales, Russell
REACTION, NCT03610711: (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

Active, not recruiting
1/2
21
US
Nivolumab, Optivo, Relatlimab, anti-LAG3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Gastroesophageal Cancer, Immune Checkpoint Inhibition
12/25
12/25
Zhang, Zhe
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Not yet recruiting
2
168
RoW
TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gastroesophageal Adenocarcinoma
09/26
09/27
Narang, Amol K
NCT00962520: Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Checkmark P2 data
Nov 2011 - Nov 2011: P2 data
Active, not recruiting
2
40
US
Erlotinib, Tarceva, capecitabine, Xeloda, Radiation Therapy, gemcitabine, Gemzar, erlotinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Genentech, Inc.
Pancreatic Cancer
04/22
04/23
NCT03767582: Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Completed
1/2
46
US
Stereotactic Body Radiation (SBRT), Nivolumab, OPDIVO, CCR2/CCR5 dual antagonist, BMS-813160, GVAX, PANC 10.05 pcDNA-1/GM-Neo vaccine, PANC 6.03 pcDNA-1/GM-Neo vaccine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
09/24
09/24
Diaz, Luis
NCT03832569: Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Active, not recruiting
1
17
US
Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Solid Tumors, Identified by NGS, PCR or IHC
02/25
02/25
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/25
10/25
Habibi, Mehran
NCT04129216: The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

Completed
2
30
US
Tamoxifen Citrate, Soltamox, Letrozole, Femara, Exemestane, Aromasin, Blueprint, Mammaprint
Johns Hopkins University, Agendia
Breast Cancer
11/22
11/22
NCT05236387: Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

Terminated
N/A
14
US
99m Tc-TM, Lymphoseek
Johns Hopkins University, Cardinal Health
Breast Cancer
05/23
06/23
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Kiess, Ana
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Recruiting
3
450
Europe, Canada, Japan, US, RoW
AAA617, (177Lu) vipivotide tetraxetan
Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
12/27
07/30
NCT02289209: Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Active, not recruiting
2
51
US
Reirradiation, MK-3475, Keytruda, pembrolizumab
Dan Zandberg, Merck Sharp & Dohme LLC
Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
08/23
08/24
NCT06322576: 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Not yet recruiting
2
10
US
177Lu-PNT2002, 177Lu PSMA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Adenoid Cystic Carcinoma Research Foundation, Progenics Pharmaceuticals, Inc.
Adenoid Cystic Carcinoma
03/30
02/35
RAVENS, NCT04037358: RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

Active, not recruiting
2
64
US
Radium-223, stereotactic ablative radiotherapy (SABR)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Defense Congressionally Directed Medical Research Program, Bayer
Prostate Cancer
12/26
12/28
NCI-2020-04699, NCT04489719: Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Recruiting
N/A
48
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride, Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM RA-223 DICHLORIDE, Radium-223 Dichloride, Xofigo
University of Washington, Bayer
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
08/25
08/28

Download Options